After Delay, FDA Approves Two JAK Inhibitors for New Indications — But Includes Significant Restrictions

After a year of controversy for janus kinase (JAK) inhibitors, the FDA has now greenlighted two JAK inhibitors for inflammatory disease indications that had been delayed for months while the agency reviewed the class of drugs for safety concerns.
Source: Drug Industry Daily